Drugs / AAV1-SERCA2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06061549 | Aug 2023 → Aug 2025 overdue | diastolic heart failure | Sardocor Corp. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV1-SERCA2a | “A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection Fraction” NCT06061549 ↗ |
| Known as | SRD-001 | “A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection Fraction” NCT06061549 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV1.SERCA2a, an Adeno-Associated Virus Serotype 1 (AAV1) vector” PMID 41546750 ↗ Jan 2026 |
| Route | Other | “Patients receive a one-time intracoronary infusion of AAV1.SERCA2A.” PMID 41546750 ↗ Jan 2026 |